Sign in

    Max Dahl • Goldman Sachs

    Max Dahl is an Investment Professional at Clearlake Capital Group with a focus on leveraged finance, structured finance, and private equity transactions. He began his career as an Investment Banker at Credit Suisse from 2018 to 2020 before joining Clearlake in December 2020. Dahl holds a cum laude BA from Pomona College, completed in 2019. His professional expertise includes advanced financial modeling and deal structuring, although there are no available public metrics on his performance, specific companies covered, or formal credentials such as securities licenses.

    Max Dahl's questions to Autolus Therapeutics PLC (AUTL) leadership

    Max Dahl's questions to Autolus Therapeutics PLC (AUTL) leadership • Q2 2025

    Question

    Representing Goldman Sachs, Max Dahl asked about the proportion of authorized centers that are actively enrolling patients and the expected revenue trajectory for the full year. He also inquired about the data timeline and success criteria for the Phase II trial in lupus nephritis.

    Answer

    CEO Christian Itin confirmed the vast majority of the 46 authorized centers have treated patients, with the newest ones now getting started. He noted that while the first half showed strong momentum, Q3 will see an impact from the CMS reimbursement changes, with a return to normal expected in Q4. He stated it is premature to provide a data timeline for the lupus nephritis study, as patient enrollment is just beginning.

    Ask Fintool Equity Research AI